Form 4: Skye Bioscience Director Annalisa Jenkins Acquires Stock Options
SEC Form 4 Filing
Director Annalisa Jenkins acquired stock options in Skye Bioscience, Inc. on February 24, 2025.
Summary
- On February 24, 2025, Annalisa Jenkins, a director of Skye Bioscience, Inc., acquired 35,000 stock options.
- The exercise price of these options is $2.89.
- The options vest in equal monthly installments over one year, starting February 21, 2025.
- The options expire on February 25, 2035.
- Following the transaction, Jenkins directly owns 35,000 derivative securities.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing. It doesn't convey any particular positive or negative sentiment.
Industry Context
This is a standard Form 4 filing, indicating a change in beneficial ownership by a company insider. It's a routine part of corporate governance and transparency.
Stakeholder Impact
- The acquisition of stock options by a director could be seen as a positive sign by shareholders, indicating confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 02/21/2025 | Vesting of stock options begins. |
| 02/24/2025 | Date of transaction: Annalisa Jenkins acquired stock options. |
| 02/25/2035 | Expiration date of the stock options. |
| 02/26/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.